论文部分内容阅读
目的 :探讨普罗布考对冠心病高脂血症患者的降脂疗效及对氧化修饰低密度脂蛋白 (OX LDL)的影响。方法 :80例冠心病合并高脂血症患者随机分为治疗组 (普罗布考 5 0 0mg/次 ,bid)和对照组 ,服药前及服药后 4周测定总胆固醇 (TC)、低密度脂蛋白 (LDL C)、甘油三酯 (TG)、载脂蛋白A1(ApoA1)、载脂蛋白B10 0 (ApoB10 0 )及血浆氧化修饰低密度脂蛋白 (OX LDL)浓度。结果 :治疗组服药 4周后TC下降 2 9.8% (P <0 .0 0 1) ,LDL C降低2 7.6% (P <0 .0 0 1) ,TG下降 2 6.3 % (P <0 .0 1) ,HDL C下降 13 .8% (P <0 .0 5 ) ,ApoB10 0 下降 19.1% (P <0 .0 0 1) ,血浆中OX LDL浓度明显减少 (P <0 .0 0 1)。对照组各项指标观察前后无明显变化。结论 :普罗布考具有降血脂、抗氧化的双重治疗作用 ,适宜冠心病合并高脂血症患者的治疗
Objective: To investigate the effect of probucol on lipid-lowering efficacy and the level of oxidized low density lipoprotein (OX LDL) in patients with coronary heart disease and hyperlipidemia. Methods: Eighty patients with coronary heart disease complicated with hyperlipidemia were randomly divided into treatment group (probucol 500 mg / time bid) and control group. Before treatment and 4 weeks after taking the medicine, total cholesterol (TC), low density lipids (LDL C), triglyceride (TG), apolipoprotein A1 (ApoA1), apolipoprotein B10 0 (ApoB10 0) and plasma oxidized low density lipoprotein (OX LDL). Results: The TC decreased by 9.8% (P <0.01), the LDL C decreased by 7.66% (P <0.01), the TG decreased by 23.3% (P <0. 0) after 4 weeks of treatment 1), HDL C decreased by 13.8% (P0.05), ApoB10 0 decreased by 19.1% (P0.01), and plasma OX LDL concentration decreased significantly (P0.01) . The control group showed no significant changes in various indicators before and after treatment. Conclusion: Probucol has the dual therapeutic effect of lowering blood fat and anti-oxidation, and is suitable for the treatment of patients with coronary heart disease complicated with hyperlipidemia